We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App

DiaSorin Receives FDA Clearance for Simplexa Test That Differentiates Between COVID-19, Flu and RSV

By LabMedica International staff writers
Posted on 10 Sep 2020
Print article
Image: LIAISON® MDX (Photo courtesy of DiaSorin Molecular LLC)
Image: LIAISON® MDX (Photo courtesy of DiaSorin Molecular LLC)
DiaSorin Molecular LLC (Cypress, CA, USA) has received FDA Clearance for its Simplexa Flu A/B & RSV Direct Gen II kit that can be run alone or alongside the Simplexa COVID-19 Direct kit, allowing for differential diagnosis of SARS-CoV-2, influenza A (Flu A), influenza B (Flu B), and respiratory syncytial virus (RSV).

The upcoming 2020/2021 flu season will be complicated by the presence of SARS-CoV-2 also circulating in the community. Viral infections caused by Flu A, Flu B, RSV and SARS-CoV-2 have similar clinical presentations, however treatment options are different and thus it is important to differentiate. Additionally, co-infection with SARS-CoV-2 and Flu A or B has been shown to cause increased severity of respiratory disease and the need for a combination therapy. The accurate diagnosis of the virus causing the infection can have major implications for the management of therapeutic regimens, infection control and community mitigation efforts.

DiaSorin’s latest generation Simplexa Flu A/B & RSV Direct Gen II kit delivers continued comprehensive strain coverage and accurate detection in an efficient and trusted sample-to-answer format that does not require extraction. Collectively, over 100 Flu A, Flu B and RSV strains have been validated, including the 2020/2021 influenza vaccine strains. The Simplexa Flu A/B & RSV Direct Gen II assay is designed for use with the LIAISON MDX instrument.

“With COVID-19 set to play a major role in the upcoming flu season, it was critical for us to have the Simplexa Flu A/B & RSV Direct Gen II assay available in time for patient samples to be tested, when needed, alongside the Simplexa COVID-19 Direct assay,” said Michelle Tabb, chief scientific officer of DiaSorin Molecular. “Detection and differential diagnosis between influenza, RSV and COVID-19 will be vital this year and we are pleased to contribute to this solution.

Print article


Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more


view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.